Unsere Publikationen

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis

Link
https://doi.org/10.1177/1756286418759895
Tags
Multiple SkleroseMS Behandlung
Jahr
2018
Autoren
Akgün K, Metz I, Kitzler HH, Brück W, Ziemssen T.
Verlag
Ther Adv Neurol Disord 2018;11.
Zum Eintrag

Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting

Link
https://doi.org/10.1177/1756286418803248
Tags
Multiple SkleroseMS Behandlung
Jahr
2018
Autoren
Albrecht P, Bjørnå IK, Brassat D, Farrell R, Feys P, Hobart J, Hupperts R, Linnebank M, Magdič J, Oreja-Guevara C, Pozzilli C, Salgado AV, Ziemssen T.
Verlag
Ther Adv Neurol Disord. 2018 Oct 5;11:1756286418803248.
Zum Eintrag

Determination of Seminal Concentration of Fingolimod and Fingolimod-Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod

Link
https://doi.org/10.1002/cpdd.424
Tags
Multiple SkleroseMS Behandlung
Jahr
2018
Autoren
David OJ, Berwick A, Pezous N, Lang M, Tiel-Wilck K, Ziemssen T, Li P, Hara H, Schmouder R.
Verlag
Clin Pharmacol Drug Dev. 2018 Feb;7(2):217-221.
Zum Eintrag

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Link
https://doi.org/10.1016/s0140-6736(18)30475-6
Tags
Multiple SkleroseMS Behandlung
Jahr
2018
Autoren
Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.
Verlag
Lancet. 2018 Mar 31;391(10127):1263-1273. Epub 2018 Mar 23.
Zum Eintrag

Letter to the editor on the paper: "The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing"

Link
https://doi.org/10.1177/1352458517726384
Tags
Multiple SkleroseMS Behandlung
Jahr
2018
Autoren
Sehr T, Proschmann U, Thomas K, Ziemssen T.
Verlag
Mult Scler J 2018;24(6):820-822.
Zum Eintrag

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Link
https://doi.org/10.1016/s1474-4422(18)30069-3
Tags
Multiple SkleroseMS Behandlung
Jahr
2018
Autoren
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators.
Verlag
Lancet Neurol. 2018 May;17(5):405-415.
Zum Eintrag

Letter to the editor to the paper: "Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis"

Link
https://doi.org/10.1016/j.msard.2018.03.013
Tags
Multiple SkleroseMS Behandlung
Jahr
2018
Autoren
Ziemssen T, Limmroth V.
Verlag
Mult Scler Relat Disord 2018;22:57-58.
Zum Eintrag

Natalizumab during pregnancy and lactation

Link
https://doi.org/10.1177/1352458517728813
Tags
Multiple SkleroseMS Behandlung
Jahr
2018
Autoren
Proschmann U, Thomas K, Thiel S, Hellwig K, Ziemssen T.
Verlag
Mult Scler J 2018;24(12):1627-1634.
Zum Eintrag
9 10 11 12 13

Publikationen durchsuchen

Publikationen filtern

Filters
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Show AllHide
Jahr
-